Julie McClure, PA
Physician Assistant · Burlington, NCNPI 1912502717
Payments from drug & device makers
Across 841 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$2K
- Johnson & Johnson$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $6K from 20 others
What the payments were for
- Food & beverage$15,17999%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 131 | $1,924 |
| Alkermes, Inc. | 102 | $1,798 |
| Johnson & Johnson | 67 | $1,788 |
| Teva Pharmaceuticals USA, Inc. | 60 | $1,270 |
| Lundbeck LLC | 57 | $1,211 |
| Otsuka America Pharmaceutical, Inc. | 70 | $1,121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $834 |
| USWM, LLC | 40 | $746 |
| Vanda Pharmaceuticals Inc. | 43 | $659 |
| Indivior Inc. | 35 | $529 |
| Neurocrine Biosciences, Inc. | 20 | $462 |
| Supernus Pharmaceuticals, Inc. | 20 | $450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $433 |
| E.r. Squibb & Sons, L.L.C. | 15 | $401 |
| Tris Pharma Inc | 19 | $370 |
| Almatica Pharma LLC | 16 | $332 |
| Sunovion Pharmaceuticals Inc. | 17 | $220 |
| Neos Therapeutics, LP | 11 | $159 |
| Merck | 9 | $157 |
| Corium, LLC | 7 | $152 |
| Axsome Therapeutics, Inc. | 5 | $108 |
| Ironshore Pharmaceuticals Inc. | 4 | $68 |
| Eisai Inc. | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$492
- INVEGA TRINZA$247
- UZEDY$242
- SPRAVATO$218
- COBENFY$127
- QELBREE$119
- INGREZZA$119
- VRAYLAR$108
How this compares
$15,282 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $232,943 |
| Abilify MaintenaAripiprazole | 45 | $127,001 |
| RexultiBrexpiprazole | 70 | $116,859 |
| CaplytaLumateperone Tosylate | 37 | $67,145 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $32,655 |
| VraylarCariprazine Hcl | 20 | $27,884 |
| SaphrisAsenapine Maleate | 23 | $22,866 |
| BelsomraSuvorexant | 27 | $11,824 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $8,140 |
| ConcertaMethylphenidate Hcl | 11 | $7,847 |
| Vilazodone Hcl | 39 | $5,452 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,091 |
| Hydroxyzine Hcl | 118 | $3,554 |
| Quetiapine Fumarate | 219 | $3,070 |
| Paliperidone ErPaliperidone | 28 | $2,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,121 | $243,860115 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $462 | $232,94327 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $834 | $67,14537 claims |
| AbbVieVraylar, Saphris | $1,924 | $50,75143 claims |
| Alkermes, Inc.Lybalvi | $1,798 | $32,65521 claims |
| MerckBelsomra | $157 | $11,82427 claims |
| Johnson & JohnsonConcerta | $1,788 | $7,84711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $433 | $4,09111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Burlington
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.